A Phase 4 interventional study of Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg and Naproxen Sodium 440 mg (BAYH6689) in Sleep, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 16 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-06-08.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of the study are to evaluate the analgesic and hypnotic efficacy of naproxen sodium and diphenhydramine combination when compared to naproxen sodium, diphenhydramine, and an ibuprofen and diphenhydramine combination
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg
Drug: Naproxen Sodium 440 mg (BAYH6689)
Drug: Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg
Drug: Naproxen Sodium 220 mg (BAYH6689)
Drug: DPH 50mg
Drug: Ibuprofen 400 mg / Diphenhydramine citrate 76 mg
Drug page: NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
Drug page: NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
Drug page: IbuprofenStudies of IbuprofenIbuprofen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
Total Sleep Time Measured by Actigraphy
Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. In calculating the total sleep time, subjects who took rescue medication were treated as "awake" from the time the rescue medication was given until the end of the sleep period. In addition, if subjects rescued before sleep onset, their total sleep time was set to zero.
Time frame: Up to 10 hours
Wake After Sleep Onset (WASO) Measured by Actigraphy
Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. WASO was defined as minutes of awake during the period of sleep onset and offset, where sleep onset is the first 20-minute block with 19 minutes of sleep.
Time frame: Up to 10 hours
Sleep Latency Measured by Actigraphy
Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Sleep latency was defined as minutes to sleep onset since dosing, where sleep onset was the first 20-minute block with 19 minutes of sleep. For subjects who had not achieved sleep onset (e.g., due to taking rescue medication before achieving sleep onset), sleep latency was considered as censored at the time of wakening.
Time frame: Up to 10 hours
Global Assessment of Study Medication as a Sleep-aid
Subject rating of following question with 0 being poor to 4 being excellent: How would you rate the study medication you received as a sleep aid?
Time frame: Up to 10 hours
Karolinska Sleep Diary - Sleep Quality
Subject rating of following question with 1 being very poor and 5 being very good: How was your sleep?
Time frame: Up to 10 hours
Karolinska Sleep Diary - Calmness of Sleep
Subject rating of following question with 1 being very restless and 5 being very calm: How calm was your sleep?
Time frame: Up to 10 hours
Karolinska Sleep Diary - Easiness to Fall Asleep
Subject rating of following question with 1 being very difficult to 5 being very easy: How easy was it to fall asleep?
Time frame: Up to 10 hours
Karolinska Sleep Diary - Premature Awakening
Subject rating of following question with 1 being woke up much too early to 3 being no: Premature awakening?
Time frame: Up to 10 hours
Karolinska Sleep Diary - Ease of Awakening
Subject rating of following question with 1 being very difficult to 5 being very easy: Ease of awakening?
Time frame: Up to 10 hours
Karolinska Sleep Diary - Well Rested
Subject rating of following question with 1 being not rested at all to 3 being completely rested: Well-rested?
Time frame: Up to 10 hours
Karolinska Sleep Diary - Sufficient Sleep
Subject rating of following question with 1 being no, definitely too little to 5 being yes, definitely enough: Did you get enough (sufficient) sleep?
Time frame: Up to 10 hours
Total Sleep Time by Subject Assessment
Subject responded to: Please estimate the number of hours and minutes you think that you slept.
Time frame: Up to 10 hours
Sleep Quality Index
Sleep Quality Index is the mean score of items, 'sleep quality', 'calm sleep', 'ease falling asleep', and 'slept throughout' on the Karolinska Sleep Diary, ranges from 1 (worst possible) to 5 (best possible).
Time frame: Up to 10 hours
Overall Rating of Severity in Categorical Pain Rating Scale Score
Subject responded to question, 'My pain at this time is' by selecting one of the following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3).
Time frame: Up to 10 hours
Change From Baseline in Categorical Pain Rating Scale Score
Subjects responded to question, 'My pain at this time is' with following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3). Subjects completed this question at baseline (post-dental surgery) and after sleep period. The following measure is the change in pain rating from baseline.
Time frame: Baseline and up to 10 hours
Overall Rating of Severity in Visual Analog Scale (VAS) Score
Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.
Time frame: At 10 hours
Change From Baseline in Visual Analog Scale (VAS) Score
Subjects completed the VAS scale at baseline (post-dental surgery) and after completion of the sleep period. Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.This measure indicates the change in pain severity rating on the VAS scale from baseline.
Time frame: Baseline and up to 10 hours
Overall Rating of Pain Relief
Subjects responded to question, "Overall, the relief from my starting pain was" by checking one of the following choices: no relief (0), a little relief (1), some relief (2), a lot of relief (3), complete relief (4).
Time frame: Up to 10 hours
Time to Rescue Medication
Subjects were allowed to "rescue" and take a non-study pain reliever if the pain was not tolerable. This measure represents for the time to taking rescue medication from the time the subject took study treatment.
Time frame: Up to 10 hours
Cumulative Proportion of Participants Taking Rescue Medication by Hour
Subjects were allowed to "rescue" and take a non-study pain reliever if the pain was not tolerable. This measure represents for the proportion of subjects who rescued in the study.
Time frame: Up to 10 hours
Global Assessment of Study Medication as a Pain Reliever
Subject responded to question, 'How would you rating this study medication you received as a pain-reliever?' with the following choices: Poor (0), Fair(1), Good(2), Very Good(3), Excellent(4)
Time frame: Up to 10 hours
Number of Times Participants Took Rescue Medication
Subjects were allowed to "rescue" and take a non-study pain reliever if the pain was not tolerable. This measure represents for the number of times rescue medication was taken by a subject.
Time frame: Up to 10 hours
Total Wake Time Measured by Actigraphy
Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.
Time frame: Up to 10 hours
Sleep Efficiency Measured by Actigraphy
Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.
Time frame: Up to 10 hours
Activity Mean Measured by Actigraphy
Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Activity mean - average movement per minute.
Time frame: Up to 10 hours
Wake Episode Measured by Actigraphy
Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Wake Episodes - # of blocks of continuous wake epochs (defined as 2 or more consecutive epochs scored as wake that ends when there is at least one epoch scored as sleep subsequent to the start of the wake epochs).
Time frame: Up to 10 hours
| Milestone | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Started | 27 | 27 | 27 | 27 | 27 | 27 |
| Completed | 27 | 27 | 27 | 27 | 27 | 27 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. In calculating the total sleep time, subjects who took rescue medication were treated as "awake" from the time the rescue medication was given until the end of the sleep period. In addition, if subjects rescued before sleep onset, their total sleep time was set to zero.
| Minutes | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Total Sleep Time Measured by Actigraphy | 339.80 (259 to 420) | 304.60 (224 to 385) | 413.89 (333 to 494) | 308.89 (228 to 389) | 76.35 (-4 to 157) | 335.68 (254 to 417) |
Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. WASO was defined as minutes of awake during the period of sleep onset and offset, where sleep onset is the first 20-minute block with 19 minutes of sleep.
| Minutes | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Wake After Sleep Onset (WASO) Measured by Actigraphy | 139.96 (70 to 210) | 190.91 (121 to 261) | 75.66 (7 to 144) | 145.67 (72 to 219) | 428.34 (351 to 506) | 129.02 (59 to 199) |
Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Sleep latency was defined as minutes to sleep onset since dosing, where sleep onset was the first 20-minute block with 19 minutes of sleep. For subjects who had not achieved sleep onset (e.g., due to taking rescue medication before achieving sleep onset), sleep latency was considered as censored at the time of wakening.
| Minutes | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Sleep Latency Measured by Actigraphy | 29.17 (9 to 50) | 32.81 (12 to 53) | 46.77 (27 to 67) | 31.58 (10 to 53) | 41.05 (18 to 64) | 36.38 (16 to 57) |
Subject rating of following question with 0 being poor to 4 being excellent: How would you rate the study medication you received as a sleep aid?
| Participants | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Poor | 1 | 6 | 2 | 4 | 6 | 0 |
| Fair | 4 | 4 | 3 | 6 | 7 | 6 |
| Good | 8 | 7 | 7 | 6 | 3 | 9 |
| Very good | 5 | 4 | 8 | 3 | 2 | 7 |
| Excellent | 4 | 1 | 3 | 1 | 0 | 0 |
Subject rating of following question with 1 being very poor and 5 being very good: How was your sleep?
| Participants | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| 1 = Very poor | 1 | 4 | 1 | 1 | 1 | 0 |
| 2 = Rather poor | 2 | 0 | 2 | 2 | 5 | 1 |
| 3 = Neither poor nor good | 6 | 11 | 3 | 7 | 3 | 10 |
| 4 = Rather good | 11 | 5 | 14 | 9 | 9 | 9 |
| 5 = Very good | 2 | 2 | 3 | 1 | 0 | 2 |
Subject rating of following question with 1 being very restless and 5 being very calm: How calm was your sleep?
| Participants | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| 1 = Very restless | 0 | 2 | 1 | 1 | 1 | 0 |
| 2 = Rather restless | 1 | 7 | 6 | 5 | 7 | 7 |
| 3 = Neither restless nor calm | 5 | 4 | 3 | 7 | 3 | 5 |
| 4 = Rather calm | 16 | 6 | 12 | 6 | 6 | 8 |
| 5 = Very calm | 0 | 3 | 1 | 1 | 1 | 2 |
Subject rating of following question with 1 being very difficult to 5 being very easy: How easy was it to fall asleep?
| Participants | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| 1 = Very difficult | 0 | 5 | 1 | 3 | 1 | 0 |
| 2 = Rather difficult | 3 | 3 | 2 | 5 | 6 | 5 |
| 3 = Neither difficult nor easy | 10 | 11 | 11 | 3 | 7 | 7 |
| 4 = Rather easy | 8 | 2 | 8 | 7 | 4 | 9 |
| 5 = Very easy | 1 | 1 | 1 | 2 | 0 | 1 |
Subject rating of following question with 1 being woke up much too early to 3 being no: Premature awakening?
| Participants | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| 1 = Woke up much too early | 5 | 6 | 2 | 6 | 8 | 5 |
| 2 = Woke up somewhat too early | 8 | 10 | 12 | 7 | 6 | 13 |
| 3 = No | 9 | 6 | 9 | 7 | 4 | 4 |
Subject rating of following question with 1 being very difficult to 5 being very easy: Ease of awakening?
| Participants | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| 1 = Very difficult | 0 | 1 | 0 | 1 | 0 | 0 |
| 2 = Rather difficult | 1 | 0 | 2 | 1 | 1 | 0 |
| 3 = Neither difficult nor easy | 1 | 7 | 5 | 1 | 3 | 4 |
| 4 = Rather easy | 15 | 8 | 8 | 15 | 9 | 14 |
| 5 = Very easy | 5 | 6 | 8 | 2 | 5 | 4 |
Subject rating of following question with 1 being not rested at all to 3 being completely rested: Well-rested?
| Participants | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| 1 = Not rested at all | 1 | 4 | 0 | 0 | 3 | 1 |
| 2 = Somewhat unrested | 13 | 14 | 14 | 12 | 14 | 17 |
| 3 = Completely rested | 8 | 4 | 9 | 8 | 1 | 4 |
Subject rating of following question with 1 being no, definitely too little to 5 being yes, definitely enough: Did you get enough (sufficient) sleep?
| Participants | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| 1 = No, definitely too little | 1 | 4 | 0 | 1 | 2 | 1 |
| 2 = No, much too little | 4 | 3 | 2 | 1 | 4 | 1 |
| 3 = No, somewhat too little | 4 | 4 | 3 | 4 | 8 | 6 |
| 4 = Yes, almost enough | 10 | 8 | 14 | 10 | 4 | 12 |
| 5 = Yes, definitely enough | 3 | 3 | 4 | 4 | 0 | 2 |
Subject responded to: Please estimate the number of hours and minutes you think that you slept.
| Minutes | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Total Sleep Time by Subject Assessment | 306.32 (231 to 381) | 309.97 (235 to 385) | 339.08 (264 to 414) | 309.23 (234 to 384) | 160.49 (85 to 236) | 299.58 (223 to 376) |
Sleep Quality Index is the mean score of items, 'sleep quality', 'calm sleep', 'ease falling asleep', and 'slept throughout' on the Karolinska Sleep Diary, ranges from 1 (worst possible) to 5 (best possible).
| Scores on a scale | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Sleep Quality Index | 3.49 (3.1 to 3.9) | 2.89 (2.5 to 3.3) | 3.40 (3.0 to 3.8) | 3.12 (2.7 to 3.5) | 2.96 (2.6 to 3.4) | 3.37 (3.0 to 3.7) |
Subject responded to question, 'My pain at this time is' by selecting one of the following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3).
| Scores on a scale | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Baseline | 2.44 ± 0.51 | 2.48 ± 0.51 | 2.48 ± 0.51 | 2.48 ± 0.51 | 2.37 ± 0.49 | 2.22 ± 0.42 |
| Post-Baseline | 1.26 ± 1.02 | 1.48 ± 1.05 | 1.26 ± 0.94 | 1.78 ± 0.97 | 2.67 ± 0.62 | 1.41 ± 1.01 |
Subjects responded to question, 'My pain at this time is' with following choices: no pain (0), mild pain (1), moderate pain (2), or severe pain (3). Subjects completed this question at baseline (post-dental surgery) and after sleep period. The following measure is the change in pain rating from baseline.
| Scores on a scale | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Categorical Pain Rating Scale Score | -1.2 (-1.5 to -0.8) | -1.0 (-1.3 to -0.6) | -1.2 (-1.5 to -0.8) | -0.7 (-1.0 to -0.3) | 0.3 (-0.1 to 0.6) | -0.9 (-1.3 to -0.6) |
Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.
| Scores on a scale | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Baseline | 76.11 ± 11.6 | 77.26 ± 13.1 | 78.19 ± 13.4 | 73.70 ± 12.3 | 79.15 ± 9.76 | 73.11 ± 10.5 |
| Post-Baseline | 32.11 ± 31.1 | 40.30 ± 33.0 | 30.33 ± 28.6 | 48.59 ± 33.4 | 84.26 ± 19.9 | 38.19 ± 32.9 |
Subjects completed the VAS scale at baseline (post-dental surgery) and after completion of the sleep period. Subjects marked a line on a 100-mm scale to indicate the severity of pain they are experiencing from 0 being no pain to 100 being worse possible pain.This measure indicates the change in pain severity rating on the VAS scale from baseline.
| Scores on a scale | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Change From Baseline in Visual Analog Scale (VAS) Score | -44.04 (-55.1 to -33.0) | -36.65 (-47.7 to -25.6) | -47.26 (-58.4 to -36.2) | -25.89 (-37.0 to -14.8) | 6.00 (-5.1 to 17.1) | -35.89 (-47.0 to -24.8) |
Subjects responded to question, "Overall, the relief from my starting pain was" by checking one of the following choices: no relief (0), a little relief (1), some relief (2), a lot of relief (3), complete relief (4).
| Participants | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| No relief | 1 | 3 | 2 | 6 | 11 | 4 |
| A little relief | 4 | 4 | 3 | 3 | 9 | 2 |
| Some relief | 8 | 7 | 5 | 4 | 5 | 5 |
| A lot relief | 12 | 10 | 13 | 11 | 2 | 13 |
| Complete relief | 2 | 3 | 4 | 3 | 0 | 3 |
Subjects were allowed to "rescue" and take a non-study pain reliever if the pain was not tolerable. This measure represents for the time to taking rescue medication from the time the subject took study treatment.
| Minutes | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Time to Rescue Medication | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Subjects were allowed to "rescue" and take a non-study pain reliever if the pain was not tolerable. This measure represents for the proportion of subjects who rescued in the study.
| Participants | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| 1 hour | 2 | 3 | 0 | 1 | 4 | 0 |
| 2 hours | 6 | 9 | 5 | 9 | 17 | 7 |
| 3 hours | 8 | 11 | 5 | 9 | 20 | 7 |
| 4 hours | 10 | 11 | 5 | 10 | 21 | 7 |
| 5 hours | 11 | 11 | 5 | 11 | 24 | 7 |
| 6 hours | 11 | 11 | 6 | 12 | 25 | 9 |
| 7 hours | 11 | 12 | 7 | 13 | 25 | 10 |
| 8 hours | 11 | 12 | 7 | 13 | 25 | 10 |
| 9 hours | 11 | 12 | 8 | 13 | 25 | 11 |
| 10 hours | 12 | 12 | 8 | 13 | 25 | 11 |
Subject responded to question, 'How would you rating this study medication you received as a pain-reliever?' with the following choices: Poor (0), Fair(1), Good(2), Very Good(3), Excellent(4)
| Participants | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Poor | 1 | 4 | 2 | 6 | 15 | 5 |
| Fair | 6 | 7 | 5 | 4 | 7 | 5 |
| Good | 7 | 7 | 4 | 7 | 5 | 4 |
| Very good | 11 | 4 | 9 | 9 | 0 | 11 |
| Excellent | 2 | 5 | 7 | 1 | 0 | 2 |
Subjects were allowed to "rescue" and take a non-study pain reliever if the pain was not tolerable. This measure represents for the number of times rescue medication was taken by a subject.
| Participants | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| 0 | 15 | 15 | 19 | 14 | 2 | 16 |
| 1 | 12 | 12 | 8 | 13 | 22 | 11 |
| 2 | 0 | 0 | 0 | 0 | 3 | 0 |
| 3 | 0 | 0 | 0 | 0 | 0 | 0 |
Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.
| Minutes | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Total Wake Time Measured by Actigraphy | 253.72 (174 to 333) | 290.03 (210 to 370) | 180.21 (100 to 260) | 285.62 (206 to 365) | 518.58 (439 to 598) | 255.20 (175 to 336) |
Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.
| Percentage of sleep time | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Sleep Efficiency Measured by Actigraphy | 57.24 (44 to 71) | 51.49 (38 to 65) | 68.87 (55 to 82) | 52.09 (39 to 66) | 12.85 (-1 to 26) | 56.70 (43 to 70) |
Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Activity mean - average movement per minute.
| Movement per minute | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Activity Mean Measured by Actigraphy | 42.09 (25 to 59) | 48.48 (32 to 65) | 26.73 (10 to 43) | 52.36 (36 to 69) | 72.43 (56 to 89) | 41.14 (24 to 58) |
Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects. Wake Episodes - # of blocks of continuous wake epochs (defined as 2 or more consecutive epochs scored as wake that ends when there is at least one epoch scored as sleep subsequent to the start of the wake epochs).
| Wake episodes | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| Wake Episode Measured by Actigraphy | 8.38 (5 to 11) | 10.86 (8 to 14) | 13.26 (10 to 16) | 9.89 (7 to 13) | 5.84 (3 to 9) | 11.98 (9 to 15) |
Collected over Treatment emergent adverse events (TEAEs) were collected after the administration of the first dose of study drug up to 5 days post drug administration, or up to 30 days after the last study drug administration if they were serious adverse events (SAEs).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | — | 0/27 (0%) | 2/27 (7.4%) |
| Naproxen Sodium 440 mg (BAYH6689) | — | 0/27 (0%) | 2/27 (7.4%) |
| Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | — | 0/27 (0%) | 3/27 (11.1%) |
| Naproxen Sodium 220 mg (BAYH6689) | — | 0/27 (0%) | 1/27 (3.7%) |
| DPH 50mg | — | 0/27 (0%) | 5/27 (18.5%) |
| Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg | — | 0/27 (0%) | 1/27 (3.7%) |
| Event | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 440 mg (BAYH6689) | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg |
|---|---|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 1/27 | 1/27 | 2/27 | 0/27 | 2/27 | 0/27 |
| VOMITINGGastrointestinal disorders | 0/27 | 0/27 | 0/27 | 0/27 | 2/27 | 0/27 |
| ABDOMINAL PAINGastrointestinal disorders | 0/27 | 1/27 | 0/27 | 0/27 | 0/27 | 0/27 |
| CONSTIPATIONGastrointestinal disorders | 0/27 | 0/27 | 0/27 | 0/27 | 1/27 | 0/27 |
| PYREXIAGeneral disorders | 0/27 | 0/27 | 1/27 | 0/27 | 0/27 | 0/27 |
| DIZZINESSNervous system disorders | 0/27 | 0/27 | 0/27 | 0/27 | 1/27 | 0/27 |
| HEADACHENervous system disorders | 0/27 | 0/27 | 0/27 | 0/27 | 1/27 | 0/27 |
| RESTLESS LEGS SYNDROMENervous system disorders | 0/27 | 0/27 | 0/27 | 0/27 | 1/27 | 0/27 |
| INSOMNIAPsychiatric disorders | 0/27 | 0/27 | 0/27 | 1/27 | 0/27 | 0/27 |
| PHARYNGOLARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 0/27 | 0/27 | 1/27 | 0/27 | 0/27 | 0/27 |
| Age, Continuous(years) | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg | Naproxen Sodium 440 mg (BAYH6689) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 19 ± 2.8 | 20 ± 2.8 | 19 ± 2.0 | 19 ± 3.0 | 19 ± 2.5 | 20 ± 2.6 | 19 ± 2.6 |
| Sex: Female, Male(Participants) | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg | Naproxen Sodium 440 mg (BAYH6689) | Total |
|---|---|---|---|---|---|---|---|
| Female | 16 | 15 | 10 | 19 | 12 | 12 | 84 |
| Male | 11 | 12 | 17 | 8 | 15 | 15 | 78 |
| Baseline Categorical Pain Rating Scale(Participants) | Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg | Naproxen Sodium 220 mg (BAYH6689) | DPH 50mg | Ibuprofen 400 mg / Diphenhydramine Citrate 76 mg | Naproxen Sodium 440 mg (BAYH6689) | Total |
|---|---|---|---|---|---|---|---|
| No pain | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mild pain | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Moderate pain | 15 | 14 | 14 | 17 | 21 | 14 | 95 |
| Severe pain | 12 | 13 | 13 | 10 | 6 | 13 | 67 |
The record gives a start of Jan 2008, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 6 years 4 months after primary completion. A results delay was requested in May 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen